Dr. Brian Levy O.D., M.Sc. -- Chief Executive Officer

Dr Levy has spent his career in ophthalmology and is a proven leader with a depth of experience in Drug and Device Development, Clinical Development and Medical Affairs. Dr. Levy has successfully led 5 New Drug Applications (NDA’s) in Ophthalmic Pharmaceuticals, all approved and commercialized.

Prior to InflammX, Dr. Levy was Chief Medical Officer at Aerie Pharmaceuticals where he was a member of the Executive team that took the company public through a successful IPO. Prior to that he spent 15 years at Bausch & Lomb as Vice President R&D and then Chief Medical Officer for the Corporation. In these evolutionary roles he was responsible for Global Clinical and Product Development, Global Product Safety and Medical Affairs. Prior to joining Bausch & Lomb, Dr. Levy was Associate Professor in the Department of Ophthalmology at California Pacific Medical Center in San Francisco, completed NEI courses in Epidemiology and Biostatistics in Vision Research and was a clinical investigator for numerous products in development and an advisor and consultant to the ophthalmic industry. Dr. Levy holds an appointment as Clinical Professor in the Department of Ophthalmology at the University of Rochester’s School of Medicine. He is a healthcare advisor to Spindletop Capital and has served on the boards of both public and private companies developing products in Ophthalmology. He received a Doctor of Optometry degree from the University of California at Berkeley and did his post-graduate work in Comparative Anatomy and Physiology of the Eye at the University of Waterloo in Canada, where he received a Master of Science degree.

David Pool -- Chief OPERATING & FinanciaL Officer

David Pool has over 35 years investment banking and venture capital experience including privatization transactions, leasing, securitizations, venture capital raising and initial public offerings. As InflammX Chief Operating & Financial Officer since establishment David’s responsibilities include overseeing the day-to-day administrative and operational functions of InflammX along with the financial and accounting functions, as well as driving InflammX's fund raising and business development activities. David has served on private company Boards of Directors including OMNI Orthopedics, a manufacturer of devices for robotic-assisted total knee replacement that was sold to the Corin Group in 2019.

Prior to InflammX, Mr. Pool was Ocunexus Therapeutics Chief Financial Officer for 13 years. David previously worked as an Investment Banker in New Zealand and New York working on IPOs, mortgage and aircraft leasing securitizations and debt and equity capital raising. David holds a Bachelor of Commerce in accounting and business management from the University of Canterbury and is a member of the Institute of Chartered Accountants of New Zealand. David is active as a volunteer in his local community as a rugby coach and is currently the President of USA Youth & High School Rugby

Colin Green PhD DSc -- Founder and chief scientific officer

Emeritus Professor Green holds the W&B Hadden Chair of Ophthalmology and Translational Vision Research at the University of Auckland, New Zealand. He has over 40 years of research experience including 12 years in France, United States (Baylor College of Medicine) and England (as a Royal Society Research Fellow and Reader, University College London). He has published >200 research manuscripts (including one in Science and two in Nature) and has an H index = 57. Dr Green has supervised 60 postgraduate students to completion. Dr Green’s own work has won the International Robert Feulgen Prize (1992), an Arthritis New Zealand Distinguished Service Award (2012), the Dame Ida Mann Lecture for Royal Australian and New Zealand College of Ophthalmologists (2012), the University of Auckland Vice-Chancellor's Commercialisation Medal (2014) and the Shorland Medal of the New Zealand Association of Scientists, 2017. His previous drug discovery, NEXAGON, a 'gap junction hemichannel modulator' for front-of-the-eye disorders is in final trials. Profesor Green’s team is world leading on the role of gap junction channels in injury and disease, with new treatments for ocular and other diseases that go beyond the treatment of clinical signs to target underlying causes. His discoveries on connexin hemichannel roles in vascular dropout and perpetuation of the inflammasome pathway impact upon the understanding of many acute and chronic disease conditions. Dr Green is an inventor on over 270 patents in thirty four patent families.

Dr. Philip ROSENFELD M.D. - Chief retina advisor

Dr. Rosenfeld is a Professor of Ophthalmology at the Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine. A specialist in vitreoretinal diseases, Dr. Rosenfeld pioneered the use of the anti VEGF drug called Avastin to treat wet AMD while he was the lead investigator in the development of Lucentis. He theorized, and then showed that a small amount of Avastin, which was approved by the FDA for the treatment of metastatic colorectal cancer, could be injected directly into the eye to help prevent blindness. He determined that this unique therapy was effective in stopping blood vessels from growing, leaking, and damaging the retina. Not only was Avastin highly effective in treating a wide range of exudative eye diseases, but it was inexpensive and quickly gained global dominance as the anti-VEGF therapy of choice saving billions of dollars worldwide. He also developed OCT-guided therapy, which decreased the need for injections and, once again, saved healthcare agencies billions of dollars. He is leader in optical coherence tomography (OCT) research and has been involved in developing novel algorithms for diagnosing and studying the progression of retinal diseases.

Dr. Rosenfeld has turned his attention to the development of novel therapies for the study of dry AMD, and has been involved in numerous clinical trials, including the first study using an intravitreal complement inhibiter. He and his team have developed OCT clinical trial endpoints that are ideally suited for the study of novel therapies for the treatment of intermediate AMD.  Dr Rosenfeld heads the medical retina division and is the medical retina fellowship director who has helped train a generation of medical retina specialists at the Bascom Palmer Eye Institute. As a clinician, researcher, educator, and lecturer, Dr. Rosenfeld brings his expertise and insights to InflammX.